What Albuminar Treats: Main Uses and Benefits

Albuminar is a therapeutic protein commonly applied in clinical settings that involve acute or unstable symptom patterns related to systemic imbalance, and is considered relevant for easing distress. The medication is applied across domains where additional symptomatic support is needed.

---

Key Therapeutic Applications

Albuminar is commonly used to help with symptoms related to systemic imbalance, particularly in situations where patients experience low blood pressure and manifestations of hypovolemic shock. It is relevant in contexts marked by increased discomfort or tension due to critically low levels of albumin (hypoalbuminemia), and is used to address symptoms that create noticeable physiological strain and fluid accumulation. It is relevant in clinical settings that involve severe trauma or extensive burns, or in situations involving conditions marked by increased physiological stress, such as chronic liver disease and Acute Respiratory Distress Syndrome (ARDS). By providing protein replacement, it contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

Quick Fact: Supports Relief for Systemic Imbalance
Albuminar is applied when symptoms related to fluid accumulation interfere with routine activities, providing supportive relief when symptoms are more noticeable.

Regulatory References

1. NIH DailyMed drug label for Albumin (Human) 5%

Who can and cannot use Albuminar?

The official eligibility profile for Albuminar (Human Albumin) is structured around absolute non-eligibility and conditional use, as defined in government regulatory documents.

Contraindicated Populations (Must Not Use):

The medication is strictly contraindicated and must not be administered to patients who have a known history of hypersensitivity or allergic reactions to human albumin products. It is also contraindicated for patients with severe anemia or severe cardiac failure, where the medication's volume-expanding effect could pose a formal, labeled risk.

Eligibility by Age Group:

Albuminar is approved for use across all major age groups, including pediatric patients, adults, and older adults. Advanced age alone does not impose specific restrictions or require routine adjustments.

Conditional and Restricted Use:

Use is restricted or conditional in patients with conditions that pose a risk of volume overload (hypervolemia), such as hypertension, cardiac insufficiency, or severe renal impairment. In these groups, the product must be used with caution as mandated by official labeling.

Pregnancy and Lactation:

Use during pregnancy is conditional, assigned Pregnancy Category C in the U.S. framework, permitted only if the clinical benefit justifies the risk. Use during lactation is determined based on the mother's clinical necessity.

Albuminar (Human Albumin) primarily involves physical and mixing incompatibilities rather than traditional drug-drug interactions, with regulatory documents stating no specific interactions with other medicinal products are known.

Incompatibilities and Mixing Restrictions

There are mandatory restrictions concerning the substances that can be combined or mixed with the Albuminar solution during preparation and administration:

• Do Not Dilute: The solution must not be diluted with Water for Injections (sterile water) alone, as this poses a risk of causing hemolysis (red blood cell destruction) in the recipient.
• Do Not Mix With: Albumin solutions must not be mixed with protein hydrolysates, amino acid mixtures, or solutions containing alcohol, as these combinations may cause precipitation of proteins within the solution.

Compatible Products and Co-Administration

Albuminar is generally compatible and may be given in conjunction with certain other common intravenous fluids. These compatible solutions include saline, dextrose, and sodium lactate solutions. When large quantities of Albuminar are administered, especially in procedures involving significant red blood cell loss, the label notes that the albumin should be supplemented with or replaced by packed red blood cells to prevent relative anemia.

Albuminar, a form of human albumin, functions as a colloid that primarily targets the intravascular compartment to modulate colloid osmotic pressure (COP). Upon intravenous administration, the protein acts as a non-signaling space-occupying solute within the circulating plasma. The molecular mass and concentration of the albumin gradient increase the intravascular COP relative to the interstitial fluid COP. This oncotic gradient generates a Starling force that mediates the movement of water and low molecular weight solutes from the extravascular, or interstitial, space into the intravascular space. This fluid mobilization directly increases the circulating plasma volume.

Furthermore, the albumin molecule possesses multiple non-specific binding sites for a diverse array of endogenous and exogenous ligands, including fatty acids, bilirubin, hormones, and various small molecules. This transport function sequesters these ligands within the circulation, influencing their systemic distribution and free concentration. Additional effects include free radical scavenging and maintaining vascular endothelial integrity through non-receptor-mediated mechanisms.

Albuminar is administered exclusively by intravenous infusion (IV) in a controlled clinical setting as a plasma expander. It is supplied as a ready-to-use IV solution in two main concentrations: 5% and 25%. The required dose is determined primarily by the adequacy of the patient’s circulating blood volume and individual clinical status, rather than solely by laboratory measurement of plasma albumin levels.

For managing an acute volume deficit (hypovolemia), the adult starting dose is typically 25 grams. This dose may be followed by an additional dose if the necessary clinical response is not achieved within 15 to 30 minutes. Conversely, treatment regimens for certain types of hypoalbuminemia may involve a dose range of 50 g to 75 g total, and for conditions like acute nephrosis, a schedule of 25 grams once daily is sometimes followed over a course of 7 to 10 days. The total daily dose infused must not exceed 2 grams per kilogram of body weight.

The preparation involves strict administration constraints: the solution may be diluted with 0.9% saline or 5% dextrose but is not to be diluted with sterile water for injection to prevent complications. If large volumes are administered, the solution should be warmed to room temperature before infusion. The solution must be used immediately once the container is opened, and the rate of infusion must always be adjusted to the patient’s individual needs.

Research Evidence / Overview of Studies

Summary of Key Findings

Research has explored whether the combination is an appropriate therapy for individuals with Type 2 diabetes. Specifically, studies have examined whether the combination is associated with lower blood sugar levels and weight loss. Findings were primarily drawn from a series of double-blind, placebo-controlled, Phase 3 randomized controlled trials (RCTs).

The evidence base focuses on two main areas: changes in metabolic markers and tolerability over the study period.

---

Efficacy and Metabolic Marker Evaluation

RCTs have been the primary method for evaluating the combination.

• HbA1c Reduction: One large-scale trial evaluated the combination by observing changes in HbA1c levels over 52 weeks. The trial involved over 1,500 participants and measured the percentage change from baseline. Across the intervention groups, the trial reported that data indicated a lower mean HbA1c level at the study conclusion compared to the placebo group.
• Weight Management: A separate meta-analysis of four pooled trials investigated associations between the combination and body weight. The analysis found that all trials reported a lower mean body weight among participants receiving the combination compared to those receiving the placebo or comparator drug at the end of the observation period.
• Mechanism of Action Comparison: Research comparing the drug's mechanism of action, which involves a dual approach, to single-target treatments was conducted. Comparative trials reported different rates of reaching specific HbA1c targets between the dual and single approaches. Studies have explored the combination’s association with changes in common diabetes symptoms.

---

Tolerability Profile

Tolerability evaluation has focused on short-term tolerability and long-term adverse events.

• Adverse Event Rates: The primary studies reported that the most common adverse events among participants were gastrointestinal in nature, including nausea, vomiting, and diarrhea. Study participant logs indicated that the frequency of these events was lower after the initial weeks of the study.
• Long-Term Profile: Another study examined long-term tolerability and reported that the combination was tolerated by a majority of participants. The incidence of major adverse cardiovascular events (MACE) was evaluated across several trials; rates reported in the intervention groups were comparable to those in the placebo control groups. Study protocols generally involved use of the drug as prescribed and monitoring for side effects. Trials involving participants with pre-existing kidney issues were also conducted.
• Quality of Life: Further studies analyzed the relationship between the combination and quality of life metrics. Some trials used validated patient-reported outcome measures (PROMs) and documented changes in scores for physical functioning and general health perception compared to baseline.

Common questions about Albuminar (FAQ)

Q: What is Albuminar used for?

A: Albuminar (Albumin Human) is officially indicated to restore and maintain circulating plasma protein levels in certain medical conditions. According to regulatory documents, it is indicated to help manage volume deficiency (low blood volume) and hypoproteinemia (low protein levels in the blood), which may occur in conditions like shock, burns, and certain liver or kidney diseases.

Q: How is Albuminar administered?

A: Albuminar is administered through intravenous infusion (directly into a vein). Official product information specifies that this treatment is always performed by a healthcare professional. The rate of administration is carefully determined and adjusted based on the individual's clinical needs, as outlined in the official product information.

Q: Does Albuminar have a lot of sodium?

A: According to the official product label, Albuminar contains sodium, which is relevant for patient management, particularly for those with specific fluid restrictions. The label states that one liter of Albuminar 5% contains 130–160 mEq of sodium, which is considered a nearly physiologic amount, meaning it is similar to the concentration found naturally in the body.

Q: What is the source material for Albuminar?

A: Albuminar is manufactured from pooled human plasma, which is the liquid component of human blood collected from voluntary donors. Official regulatory information confirms that the manufacturing process includes specific steps to treat the plasma and ensure product safety.

Q: Is there a risk of transmitting diseases with Albuminar?

A: Regulatory documents indicate that the risk of transmitting infectious agents is considered remote. This is because the human plasma is screened and the manufacturing process includes steps, such as pasteurization (heat treatment), that are specifically designed to reduce the risk of transmitting viruses.

How to Store and Dispose of Albuminar?

Albuminar (Albumin [Human]) must be stored strictly according to regulatory standards to maintain its stability.

---

Storage and Handling

The product must be stored at a temperature between 2 C and 25 C (36 F to 77 F). Solutions must not be frozen; frozen vials must be discarded. To ensure the protein remains effective, the container must be kept in its original packaging to protect the contents from light. As Albuminar contains no preservative, administration must not begin more than 4 hours after the container is entered or the stopper is pierced. The product must be kept out of the reach of children.

---

Disposal Requirements

Any unused portion or partially used vials must be discarded immediately. Disposal of the unused product, residues, and containers must be carried out in compliance with all local, regional, and national regulations.